Sphere Bio

Sphere Bio is a life sciences company that has developed a platform for single-cell analysis and isolation based on its proprietary picodroplet microfluidic technology. The company's flagship product, the Cyto-Mine® Chroma, is a fully automated system that can encapsulate, analyze, sort, and dispense viable single cells at high throughput.

This technology is particularly applicable in the fields of cell-based therapy and synthetic biology. For cell-based therapies, the platform allows for the characterization of individual cells, which is a critical step in ensuring the safety and efficacy of these treatments. In synthetic biology, the high-speed nature of picodroplets is well-suited for the rapid screening and evolution of engineered cells.

Sphere Bio's business model involves the sale of its Cyto-Mine® Chroma instrument and the associated consumables. The company serves a global market through a direct sales force and a network of distributors. Its client base consists of research institutions, pharmaceutical companies, and biotechnology firms engaged in cell-based research and development.

Keywords: single-cell analysis, picodroplet technology, microfluidics, cell-based therapy, synthetic biology, Cyto-Mine, cell isolation, high-throughput screening, antibody discovery, monoclonality